[Evidence-based pharmacological metaphylaxis of stone disease].
Approximately one-fourth of urolithiasis patients are at high risk for recurrent stone formation or severe metabolic disturbances. These patients need specific metaphylaxis for effective stone prevention, adjusted to their individual metabolic risk. Recent recommendations for the pharmacological treatment of stone diseases are summarized in this article. For the different treatment options, evidence from the literature was assessed. In addition, a follow-up concept for pharmacologically treated high-risk stone formers is discussed.
Straub
M
M
Urologische Klinik und Poliklinik der Technischen Universität München, Klinikum rechts der Isar, München. michael.straub@lrz.tum.de
Hautmann
R E
RE
D019317:Evidence-Based Medicine; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007669:Kidney Calculi / Q000737:chemistry / Q000209:etiology / Q000517:prevention & control; D008134:Long-Term Care; D012307:Risk Factors; D055502:Secondary Prevention; D014545:Urinary Calculi / Q000737:chemistry / Q000209:etiology / Q000517:prevention & control*